Clinical Trial Update: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of Vatelizumab in relapsing-remitting multiple sclerosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Vatelizumab (Vatelizumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED